Video Experimental Relacionado

Updated: Jul 14, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Síntesis, caracterización y capacidad de coordinación de metales de compuestos multifuncionales que contienen

Tim Storr¹, Michael Merkel, George X Song-Zhao

¹Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia, V6T 1Z1, Canada.

Journal of the American Chemical Society

|May 22, 2007

Resumen

Los investigadores desarrollaron nuevos compuestos, H2GL1 y H2GL2, para quelar metales como el cobre y el zinc involucrados en la patogénesis de la enfermedad de Alzheimer (EA). Estos agentes muestran capacidad antioxidante e inhiben la agregación de beta amiloide, ofreciendo estrategias terapéuticas potenciales para la enfermedad de Alzheimer.

Área de la Ciencia:

Química medicinal Química medicinal es el campo de la química medicinal.
La neurociencia es la neurociencia.
La bioquímica es la bioquímica.

Sus antecedentes:

Las interacciones disfuncionales entre los iones metálicos (Cu, Zn, Fe) y el péptido amiloide-beta (Aβ) están implicadas en la etiología de la enfermedad de Alzheimer (EA).
La generación catalizada por metales de especies reactivas de oxígeno (ROS) exacerba la neurodegeneración en la enfermedad de Alzheimer.
La terapia de quelación presenta una estrategia prometedora para interrumpir las interacciones aberrantes entre metales y péptidos y combatir la enfermedad de Alzheimer.

Objetivo del estudio:

Desarrollar nuevos compuestos multifuncionales que contienen carbohidratos para la quelación y redistribución de metales dirigida al cerebro.
Investigar las propiedades y el potencial terapéutico de los compuestos sintetizados H2GL1 y H2GL2 en el contexto de la enfermedad de Alzheimer.

Principales métodos:

Síntesis y caracterización de dos nuevos compuestos: H2GL1 y H2GL2.
Potentiometría, UV-vis y espectroscopia de RMN de 1H para determinar las constantes de acidez y los sitios de protonación.
Ensayos de antioxidantes in vitro y evaluación de la inhibición de la agregación de Aβ1-40 inducida por metales.
Cristalografía de rayos X para la determinación estructural de complejos metálicos.

Principales resultados:

H2GL1 y H2GL2 exhiben una capacidad antioxidante significativa.
Ambos compuestos reducen efectivamente la agregación de Aβ1-40 inducida por Zn2+ y Cu2+ in vitro.
H2GL1 demuestra una capacidad de coordinación superior a pH fisiológico para Cu2+ sobre Zn2+.

Conclusiones:

Los agentes multifuncionales desarrollados H2GL1 y H2GL2 son prometedores como candidatos terapéuticos para la enfermedad de Alzheimer.
Su capacidad para quelar metales neurotóxicos e inhibir la agregación de Aβ respalda su potencial en las estrategias de tratamiento de la EA.

Más Videos Relacionados

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

Videos de Conceptos Relacionados

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Dementia l: Introduction

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...